Herlitz J, Hjalmarson A, Swedberg K, Vedin A, Waagstein F, Waldenström A, Wilhelmsson C
Int J Cardiol. 1986 Mar;10(3):291-301. doi: 10.1016/0167-5273(86)90010-0.
The mortality and morbidity were assessed during a 2-year follow-up in an acute intervention trial in suspected acute myocardial infarction with metoprolol (a selective beta 1-blocker). On admission to the trial, the 1395 participating patients were randomly allocated to metoprolol or placebo for 3 months. Thereafter, if there was no contraindication, patients with infarction and/or angina pectoris were continued on metoprolol for 2 years. A lower mortality was observed after 3 months in patients randomised to metoprolol. The difference remained after 2 years. The difference in 2-year mortality rate was restricted to patients randomised early after onset of pain. Late infarction was observed more often in the placebo group during the first 3 months. When the two groups thereafter were treated similarly, the difference successively declined and did not remain after 2 years. A similar incidence of angina pectoris was observed in the two groups at each check up. During the early recovery period, more patients in the metoprolol group returned to work. No such difference was observed later on.
在一项针对疑似急性心肌梗死患者使用美托洛尔（一种选择性β1受体阻滞剂）的急性干预试验中，对患者进行了为期2年的随访，以评估死亡率和发病率。在试验入组时，1395名参与患者被随机分配接受美托洛尔或安慰剂治疗3个月。此后，如果没有禁忌症，患有心肌梗死和/或心绞痛的患者继续服用美托洛尔2年。随机分配接受美托洛尔治疗的患者在3个月后观察到死亡率较低。2年后这种差异仍然存在。2年死亡率的差异仅限于疼痛发作后早期随机分组的患者。在最初3个月内，安慰剂组观察到更多的晚期梗死病例。此后两组接受相似治疗时，差异逐渐减小，2年后不再存在。每次检查时两组心绞痛的发生率相似。在早期恢复期，美托洛尔组更多患者恢复工作。后期未观察到此类差异。
